IP Library Granted Patent US 8,642,739
Granted Patent B2
US 8,642,739 · App. 13/157,815 · Granted Feb 4, 2014

Nuclear factor κB inducing factor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,739
App. No.
13/157,815
Granted
Feb 4, 2014
Kind
B2
Abstract

The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NFκB induction in a patient, methods and compositions for lowering NFκB induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.

Claims (9)

1. An isolated and purified nuclear factor kappa B inducing factor (NFIF) 14b polypeptide which induces nuclear factor kappa B (NFκB) in a patient comprising the amino acid sequence of SEQ ID NO:1.

2. An isolated antibody which specifically binds the NFIF-14b polypeptide of claim 1 .

3. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

4. A composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.

5. The composition of claim 3 , further comprising a biocompatible solution.

6. A method of increasing expression of NFκB in a patient comprising introducing the composition of claim 3 into the body of the patient.

7. A method of inhibiting inflammation comprising administration of the composition of claim 4 to a patient.

8. An isolated and purified NFIF-14b polypeptide which induces NFκB in a patient comprising the amino acid sequence encoded by nucleotides 394 to 1362 of SEQ ID NO: 3.

9. The NFIF-14b polypeptide of claim 8 , further comprising lower NFκB inducing activity than the NFIF-14b polypeptide of claim 1 .

Assignments (6)
MERGER Recorded Jan 19, 2015
From: AVENTIS PHARMACEUTICALS INC.
To: AVENTISUB LLC
Reel/Frame 034781/0334 →
CERTIFICATE OF CONVERSION Recorded Dec 9, 2014
From: AVENTISUB INC.
To: AVENTISUB LLC
Reel/Frame 034566/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2011
From: AVENTIS PHARMA S.A.
To: AVENTIS PHARMACEUTICALS PRODUCTS INC.
Reel/Frame 027222/0685 →
CHANGE OF NAME Recorded Nov 14, 2011
From: AVENTIS PHARMACEUTICALS PRODUCTS INC.
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 027226/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2011
From: KAPLOW, JUNE; HAWS, THOMAS F., JR.
To: AVENTIS PHARMACEUTICALS PRODUCTS INC.
Reel/Frame 027194/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2011
From: DENEFLE, PATRICE; ROSIER-MONTUS, MARIE-FRANCOISE
To: AVENTIS PHARMA S.A.
Reel/Frame 027194/0308 →